Several studies in brain cancer in collaboration with the EORTC Brain Tumor Group are in progress:
- Two studies of temozolomide and radiation therapy in anaplastic glioma in respectively, patients with and without co-deletion of chromosomes 1p and 19q.
- A phase II study on atypical and malignant meningioma is completing recruitment in a few months. An international collaboration is being developed for conducting the follow-up phase III confirmatory trial.
The results of a number of other joint studies with the EORTC Brain Tumor Group have just delivered their first results:
- The joint trial with the EORTC Brain Tumor Group on the use of temsirolimus in non-methylated glioblastomas, temozolomide and radiation therapy in elderly glioblastoma patients completed recruitment in October 2012 and should deliver its results by the end of 2013.
- The CENTRIC study on the use of cilengitide in combination with standard treatment for glioblastoma patients with methylated MGMT gene promoter completed recruitment and results showed no benefit of the addition of cilengitide (Press Release).
- The results of the phase III trial comparing primary chemotherapy with temozolomide versus radiotherapy in patients with low grade gliomas stratified for genetic 1p loss will be reported in Spring 2013.
- A further collaborative study, EORTC trial 26112-22112 Irradiance, is in preparation. RTQA delivery will be managed by the RTQA team.
In the field of breast cancer:
- A fruitful collaboration with the Trans-Tasman Radiation Oncology Group (TROG) within the DCIS (ductal carcinoma in situ) study is actively recruiting.
- The collaborative study with the Scottish Cancer trial breast group SUPREMO study is completing recruitment.
- Results of the first analysis of EORTC trial 22922/10925 evaluating the value of irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer will be available this Spring and should be reported at the European Cancer Conference in Fall 2013.
- The first results of the joint trial with the EORTC Breast Cancer Group testing axillary radiation versus axillary surgery (AMAROS) have been submitted for presentation at ASCO 2013.
- The long term update of the boost/no boost study in early breast cancer is being prepared for the end of 2013.
- New study concepts revolving around partial irradiation of the breast and neoadjuvant treatments are being developed.
For prostate cancer:
- The joint trial with the EORTC Genito-Urinary Cancer Group, EORTC trial 22043/30041 on postoperative radiotherapy for prostatic carcinoma, is running again after thoroughly modifying the protocol according to routine practices in Europe to allow patients to enter the study in the early salvage setting.
- Collaboration with the French GETUG PEACE trials is being set up.
- Collaboration with the Radiation Therapy Oncology Group (RTOG) on their phase III trial testing androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high-risk prostate cancer is being evaluated.
- Analysis of EORTC trial 22991 for intermediate risk patients receiving radiation therapy with or without short term hormonal therapy will be performed later this year.
- Further projects are being developed in collaboration with the EORTC Genito-Urinary Cancers group.
- A fruitful collaboration with the Trans-Tasman Radiation Oncology Group (TROG) within the TOPGEAR trial dedicated to preoperative treatments of esogastric carcinomas is starting.
- RTOG led study on locally advanced pancreas cancer is being launched.
- A project on anal cancer (PARADAC) has been completed and will be reported at the Europan Cancer Conference in Fall 2013. This meta-analysis is a joint project concerning more or less all recent anal cancer studies out of which it is hoped to plan future work in this area.
- The long term results of the locally advanced rectal cancer trial testing the addition of chemotherapy preoperatively and in the adjuvant setting were submitted for presentation at ASCO 2013.
- The LungTech trial aiming to evaluate the role and toxicity of stereotactic radiotherapy delivered to central lung tumors has been written in close collaboration with the Imaging Group and QA platform and will be launched soon.
- Collaboration in the French Lung ART study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement is starting.
- A joint protocol with the EORTC Soft Tissue and Bone Sarcoma Group has recently started in the field of retroperitoneal tumors testing the role of preoperative radiotherapy. ROG is managing the RTQA of this trial.
- A very important and innovative trial in collaboration with the DAHANCA group is expected to start in the coming months. This trial is testing radiosensitization of accelerated fractionated chemo-radiotherapy in squamous cell carcinoma of the head and neck and aims to validate at the same time a genomic signature of hypoxia that should enable the identification of the patients most likely to benefit from the hypoxic radiosensitizer nimorazole (Nimoral).